Amgen Plans to launch 6 new biosimilars beginning in 2017
what does this mean for momenta? buyout or elimination?
on one hand, another biosimilar competitor enters the fold
on the other , an 800lb gorilla to push congress for clarity/expediency on pathway, and sic their lobbyists against other pharmas' antibiosimilar agendas